Mutlu Hizal
Ankara, Turkey
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study).
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: March 01, 2026
Synergistic prognostic effect of the renin-angiotensin-aldosterone system and immune-checkpoint inhibition in advanced lung cancer: The SPERICIL study.
Journal: International journal of cancer
Published: May 10, 2025
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer.
Journal: Expert review of anticancer therapy
Published: April 09, 2025
Long-Term Outcomes of Patients Undergoing Conversion Surgery After Induction Chemotherapy: Turkish Oncology Group Study.
Journal: Medicina (Kaunas, Lithuania)
Published: March 06, 2025
Large Unstained Cells: A Predictive Biomarker for Recurrence and Survival in Resected Gastric Cancer.
Journal: Medicina (Kaunas, Lithuania)
Published: December 08, 2024
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study.
Journal: BMC cancer
Published: August 03, 2024
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.
Journal: Clinical breast cancer
Published: June 29, 2024
Interleukin-21 and Interleukin-23 levels in familial Mediterranean Fever before and after treatment: the role of cytokines in disease pathogenesis.
Journal: Scientific reports
Published: May 16, 2024
Tamoxifen related chorioretinal structural changes.
Journal: Cutaneous and ocular toxicology
Published: June 05, 2023
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Journal: Future oncology (London, England)
Published: May 03, 2023
Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations.
Journal: Journal of cancer research and therapeutics
Published: April 03, 2023
Last Updated: 09/26/2026